Literature DB >> 2814209

C3-containing serum immune complexes in patients with systemic lupus erythematosus: correlation to disease activity and comparison with other rheumatic diseases.

C Huber1, A Rüger, M Herrmann, F Krapf, J R Kalden.   

Abstract

Although testing for circulating immune complexes (CIC) is regarded as a useful, complementary, laboratory parameter in the differential diagnosis and management of immune complex-induced vasculitis syndromes, there is still an uncertainty with regard to assay systems used for the demonstrated of soluble immune complexes. This is partly due to difficulties in the reproducibility, handling and principle limitations of available test systems for the assessment of soluble immune complexes in body fluids. In the present communication a modification of the anti-C3 test for the determination of CIC was developed using nitrocellulose as a solid phase matrix. IgG-, IgA- and IgM-containing CIC were determined and quantified using standard immune complex preparations. When 39 sera of SLE patients, 12 sera of patients with vasculitis syndromes, 10 sera of rheumatoid arthritis patients and 11 sera of patients with ankylosing spondylitis were tested, predominantly IgG-containing CIC could be demonstrated. Only in SLE patients was a significant amount of other immunoglobulin isotypes detected in CIC. In these patients a significant difference of IgG-containing CIC levels was found with regard to patients with high and low disease activity (P less than 0.0001). A significant correlation was also established between IgG-containing CIC and anti-dsDNA antibodies (P less than 0.001). In a longitudinal study the isotypes in the isolated CIC were found to be constant.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2814209     DOI: 10.1007/BF00270246

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  34 in total

Review 1.  The biology and detection of immune complexes.

Authors:  A N Theofilopoulos; F J Dixon
Journal:  Adv Immunol       Date:  1979       Impact factor: 3.543

2.  Evidence for an ester linkage between the labile binding site of C3b and receptive surfaces.

Authors:  S K Law; N A Lichtenberg; R P Levine
Journal:  J Immunol       Date:  1979-09       Impact factor: 5.422

3.  Detection and partial characterization of circulating immune complexes with solid-phase anti-C3.

Authors:  A B Pereira; A N Theofilopoulos; F J Dixon
Journal:  J Immunol       Date:  1980-08       Impact factor: 5.422

4.  The value of three immune complex assays in the management of systemic lupus erythematosus: an assessment of immune complex levels, size and immunochemical properties in relation to disease activity and manifestations.

Authors:  S A Cairns; A London; N P Mallick
Journal:  Clin Exp Immunol       Date:  1980-05       Impact factor: 4.330

5.  A PEG-precipitation laser nephelometer technique for detection and characterization of circulating immune complexes in human sera.

Authors:  F Krapf; D Renger; I Schedel; K Leiendecker; H Leyssens; H Deicher
Journal:  J Immunol Methods       Date:  1982-10-15       Impact factor: 2.303

6.  IgA containing immune complexes in rheumatoid vasculitis and in active rheumatoid disease.

Authors:  M L Westedt; M R Daha; E de Vries; R M Valentijn; A Cats
Journal:  J Rheumatol       Date:  1985-06       Impact factor: 4.666

7.  IgA- and insulin-containing (C3-fixing) circulating immune complexes in diabetes mellitus.

Authors:  G Triolo; E Giardina; A Rinaldi; G D Bompiani
Journal:  Clin Immunol Immunopathol       Date:  1984-02

8.  Reduced complement-mediated immune complex solubilizing capacity and the presence of incompletely solubilized immune complexes in SLE sera.

Authors:  G Baatrup; I Petersen; J C Jensenius; S E Svehag
Journal:  Clin Exp Immunol       Date:  1983-11       Impact factor: 4.330

9.  The specific detection of IgA in immune complexes.

Authors:  R H Kauffmann; L A Van Es; M R Daha
Journal:  J Immunol Methods       Date:  1981       Impact factor: 2.303

10.  IgA-containing circulating immune complexes in dermatitis herpetiformis, Henoch-Schönlein purpura, systemic lupus erythematosus and other diseases.

Authors:  R P Hall; T J Lawley; J A Heck; S I Katz
Journal:  Clin Exp Immunol       Date:  1980-06       Impact factor: 4.330

View more
  6 in total

1.  Immunoglobulin isotype composition of circulating and intra-articular immune complexes in patients with inflammatory joint disease.

Authors:  A D Crockard; J M Thompson; M B Finch; T A McNeill; A L Bell; S D Roberts
Journal:  Rheumatol Int       Date:  1991       Impact factor: 2.631

2.  Endothelial cell damage in rheumatoid disease correlates with complement consumption and immune complexes.

Authors:  A D Blann
Journal:  Rheumatol Int       Date:  1991       Impact factor: 2.631

3.  C1q-bearing immune complexes induce IL-8 secretion in human umbilical vein endothelial cells (HUVEC) through protein tyrosine kinase- and mitogen-activated protein kinase-dependent mechanisms: evidence that the 126 kD phagocytic C1q receptor mediates immune complex activation of HUVEC.

Authors:  S Xiao; C Xu; J N Jarvis
Journal:  Clin Exp Immunol       Date:  2001-09       Impact factor: 4.330

4.  T cell activation by soluble C1q-bearing immune complexes: implications for the pathogenesis of rheumatoid arthritis.

Authors:  K Jiang; Y Chen; C-S Xu; J N Jarvis
Journal:  Clin Exp Immunol       Date:  2003-01       Impact factor: 4.330

5.  FcγRIIA expression accelerates nephritis and increases platelet activation in systemic lupus erythematosus.

Authors:  Imene Melki; Isabelle Allaeys; Nicolas Tessandier; Benoit Mailhot; Nathalie Cloutier; Robert A Campbell; Jesse W Rowley; David Salem; Anne Zufferey; Audrée Laroche; Tania Lévesque; Natalie Patey; Joyce Rauch; Christian Lood; Arnaud Droit; Steven E McKenzie; Kellie R Machlus; Matthew T Rondina; Steve Lacroix; Paul R Fortin; Eric Boilard
Journal:  Blood       Date:  2020-12-17       Impact factor: 22.113

6.  Neutrophil FcγRIIA availability is associated with disease activity in systemic lupus erythematosus.

Authors:  Anders A Bengtsson; Helena Tyden; Christian Lood
Journal:  Arthritis Res Ther       Date:  2020-05-29       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.